Abstract
Radioimmunotherapy (RIT) is an emerging treatment option for non-Hodgkin's lymphoma. Only Zevalin (Bayer Schering Pharma) radiolabeled with yttrium 90 ((90)Y) is approved in France for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. This radioimmunotherapeutic agent consists of ibritumomab, a murine anti-CD20 monoclonal antibody, conjugated to the metal chelator tiuxetan for retention of the beta emitter (90)Y. This review presents the concept of RIT. The pharmacological characteristics of [(90)Y]-ibritumomab tiuxetan, the specificity of its preparation and its special precautions for use will be described. The other radionuclides and antibodies in development will also be mentioned.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD20 / immunology
-
Chelating Agents / administration & dosage
-
Clinical Trials, Phase III as Topic
-
Drug Delivery Systems
-
Female
-
Hematologic Diseases / chemically induced
-
Humans
-
Lymphoma, B-Cell / radiotherapy*
-
Male
-
Multicenter Studies as Topic
-
Pregnancy
-
Pregnancy Complications, Neoplastic / radiotherapy
-
Radioimmunotherapy* / adverse effects
-
Randomized Controlled Trials as Topic
-
Tissue Distribution
-
Yttrium Radioisotopes / adverse effects
-
Yttrium Radioisotopes / pharmacokinetics
-
Yttrium Radioisotopes / therapeutic use*
Substances
-
Antibodies, Monoclonal
-
Antigens, CD20
-
Chelating Agents
-
Yttrium Radioisotopes
-
ibritumomab tiuxetan